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Campath-1H (alemtuzumab) is used during conditioning to
prevent graft-versus-host disease and improve engraftment.
Pharmacokinetic data have shown that a commonly employed
dose of alemtuzumab (20 mg/day x 5, total dose 100 mg) results
in potentially lympholytic alemtuzumab levels for 50 days
post-transplant. Delayed alemtuzumab clearance might con-
tribute to increased incidence of viral infections. We there-
fore studied the effect of a reduced dose of alemtuzumab (20
mg/day x 2, total dose 40 mg) on CMV reactivation. Nine
patients (6 male, 3 female; median age 41 yrs, range 22-55 yrs)
underwent allogeneic stem cell transplantation (7 MUD, 2
MRD) for a variety of hematologic malignancies after condi-
tioning with thiotepa/TBI/alemtuzumab (7 patients) or ﬂudara-
bine/melphalan/alemtuzumab (2 patients). Five patients were at
risk for CMV reactivation (patient or donor CMV seropositive).
Alemtuzumab was administered IV on day -5 and -1 prior to
stem cell infusion. CMV reactivation was checked weekly by
CMV pp65 antigenemia testing in at-risk patients. All patients
received leukocyte depleted blood products (third generation
ﬁlter). All patients engrafted. Four out of ﬁve patients at-risk
(80%) developed CMV reactivation at a median of 28 (range
17-32) days post-transplant. No CMV infection occurred in
low-risk patients (patient and donor both CMV seronegative).
CMV reactivation was treated with IV ganciclovir induction for
a minimum of two weeks, followed by IV or PO (val)ganciclovir
maintenance. Two patients had a febrile illness at the time of
CMV reactivation, however no evidence of CMV disease was
found on imaging studies and/or biopsies. Repeated reactivation
occurred in two patients, and was responsive to retreatment
with ganciclovir or foscarnet with the addition of IVIG. No
patient died from CMV related complications. We conclude
that early CMV reactivation remains a frequently encountered
problem after conditioning regimens containing reduced dose
alemtuzumab. CMV prophylaxis should be considered in at-risk
patients.
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SEX STREOID ABLATION THERAPY RESTORES THYMIC FUNCTION AND
ENHANCES HEMOPOIESIS AND LYMPHOPOIESIS FOLLOWING ALLOGE-
NEIC AND AUTOLOGOUS STEM CELL TRANSPLANTATION
Sutherland, J.S.1, Goldberg, G.L.1, Heng, T.1, Muirhead, J.L.2, Prince,
M.3, Schwarer, A.P.2, Boyd, R.L.1 1. Dept Path. Immunol. Monash
University Medical School, Prahran, VIC, Australia; 2. Bone Marrow
Transplantation,Alfred Hospital, Prahran, VIC, Australia; 3. Haema-
tology and Medical Oncology, Peter MacCallum Cancer Institute, Mel-
bourne, VIC, Australia.
Opportunistic infection, morbidity and mortality are common
following HSC transplantation because of the failure to regen-
erate an adequate immune system. This is due to the severe sex
steroid induced thymic atrophy that occurs with age. Using
surgical or temporary chemical (LHRH/GnRH) castration we
have shown that blocking sex steroids profoundly enhances
thymus function and immune capacity in adult and aged mice.
This involved triggering proliferation of the early thymocyte
precursors, reduction of apoptotic cells and restored thymic
architecture. In addition, in mouse BMT models there was a
signiﬁcant enhancement of BM function and levels therein of
HSC in castrated mice. The HSC were readily incorporated
into the marked regeneration of the thymus. Thus, sex steroid
ablation enhances immune regeneration both at the HSC (BM)
and intrathymic levels. We then examined prostate cancer pa-
tients undergoing routine sex steroid ablation therapy. They
had a signiﬁcant increase in blood T lymphocytes (importantly
CD4 naive TREC) and NK cells, by 4-months post-treat-
ment. This lead to clinical trials using an LHRH agonist to
ablate sex steroids in patients receiving allogeneic or autologous
peripheral blood HSC transplantation (PBST). Compared to
control patients (no LHRH-A treatment), there was ﬁrstly a
signiﬁcantly decreased time to engraftment with both autolo-
gous and allogeneic PBST LHRH-A recipients showing signif-
icant increases in neutrophil counts, total WBC and lymphocyte
counts within the ﬁrst month post-transplant compared to con-
trols. In addition there was a signiﬁcant increase in CD34
stem cell numbers and NK cells in the autologous transplant
recipients who had received the LHRH-A. Importantly the
allogeneic recipients in particular showed an increase in total
and naive (CD45RACD62LCD45RO-; TREC)T cell
numbers in the blood at all time-points post-transplant com-
pared to controls. Patients receiving the LHRH-A treatment
also demonstrated a signiﬁcantly increased in vitro proliferative
responsiveness to TCR stimulation and Tetanus Toxin. These
studies set a fundamentally new approach for the treatment of
many clinically based T-cell disorders.
LEUKEMIA
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BONE MARROW ANGIOGENESIS DECREASES AFTER STEM CELL TRANS-
PLANTATION FOR TREATMENT OF LEUKEMIA
Shariftabrizi, A.1, Tavangar, M.2, Gholibeikian, S.1, Alimoghadam,
K.1, Ghavamzadeh, A.1 1. Dr Shariatii Hospital, Tehran, Tehran,
Islamic Republic of Iran; 2. Dr Shariatii Hospital, Tehran, Tehran,
Islamic Republic of Iran.
Background: Bone marrow transplantation is an important
mode of therapy in adult leukemia pateinets. Increased bone
marrow angiogenesis is shown to participate in the progression
of leukemia by direct stimulatory effect of the cytokine secreted
by endothelial cells on the proliferation of leukemia cells, thus
the bone marrow angiogenesis might be a contributory factor in
relapse and also response to therapy. Previous studies have
shown that bone marrow angiogenesis might decrease after stem
cell transplantation in multiple myeloma patients. Aims: To
study whether bone marrow transplantation for the treatment of
leukemia affects the bone marrow vascular density and to clarify
its clinical signiﬁcance. Materials and methods: Pre- and post-
transplant (30 days after transplantation) bone marrow biopsy
samples of 13 patients (3 autologous, 10 allogenic) including 9
AML and 4 ALL patients were evaluated using immunohisto-
chemical staining for vWF. All the vessels in the bone marrow
biopsy core were counted and results were corrected for the
bone marrow biopsy length .The correlation between the de-
gree of decrease in angiogenesis and relapse and Graft-Versus-
Host-Disease was also studied. Results: The bone marrow
angiogenesis was signiﬁcantly decreased after one month of
chemotherapy (Mean pre-transplant vascular number  5.6/mm
/-0.9 SEM, Mean post-transplant vascular number  1.6/mm,
/- 0.26 SEM, P  0.001).There was no correlation between
the degree of angiogenesis and bone marrow cellularity (which
returned to near -normal levels at the time of post-transplant
biopsy).The changes in bone marrow vascular density also did
not correlate with the type of transplant, relapse or the occur-
rence of Graft-Versus-Host-Disease. Discussion: A signiﬁcant
and robust decrease in the bone marrow angiogenesis after stem
cell transplantation for leukemia was shown. This might be a
contributing factor in excellent results of bone marrow trans-
plantation for leukemia by decreasing proliferation stimula-
tory cytokines from the endothelial cells.The lack of correla-
tion between relapse and decrease in bone marrow density
might be attributable to the multifactorial nature of relapse in
leukemia.
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AML TRANSPLANTATION: AUTOLOGOUS VS ALLOGENEIC
Ghavamzadeh, A., Bahar, B., Gholibeikian, S., Safavifar, F., Iravani,
M., Jahani, M. Hematology-Oncology & BMT Research Center, Teh-
ran, Islamic Republic of Iran.
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Introduction: There are two types of Blood and Marrow trans-
plantation, which are performed in treating course of patients with
AML. Assessment of outcome, efﬁcacy and adverse effects of each
method is very important, in choosing the right protocol for
patients. Method: 138 transplanted patients 68 (49.3%) male and
70(50.7%) female, with diagnosis of AML were included in present
study during 1992-2003.The median age was 23 (ranged 3-58 yrs).
Seventy-three patients (52.9 %) patients received transplantation
as Allogeneic and 65 (47.1%) patients as Autologous. The source of
stem cells was Bone marrow in 40 (29 %), Peripheral blood in 97
(70.3 %) and BM plus PBSC in 1(0.7%) patients respectively.
Conditioning regimen for the Allogeneic was Busulphan 4 mg/kg
for 4 days plus Cyclophosphamide 60 mg/kg for 2 days and for
Autologous were ARA-C 100 mg/m2 /BD for 3 days plus VP16 500
mg/m2 for 3 days and Cyclophosphamide 60 mg/kg for 2 days.
Results: 50 out of 138 (36.2%) patients were died. The most
common leading causes of death were relapse in 26 (18.8%) cases
and the acute and chronic GVHD in 7(5%) cases. 10 years overall
survival (which was test by Kaplan-Meier) in Allogeneic and Au-
tologous transplantation was 52%, The relapse frequency in Allo-
geneic and Autologous was 11 % and 28 % respectively, which was
statistically signiﬁcant by Pearson Chi-Square test (P-value  0.01
and Odds Ratio  3.91). Patients in allogeneic and Autologous
groups were compared according to confounding factors such as
age, sex and stem cell source and there were not any signiﬁcant
difference. Conclusion: Despite a remarkable difference in relapse
frequency among these two groups we showed that there were not
any signiﬁcant difference in 10 years overall survival between
allogeneic and autologous cases. Furthermore we conclude that
Autologous PBSC transplantation is easier, cost effective and has
less morbidity.
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CR1 ACUTE MYELOID LEUKEMIA AND HLA-IDENTICAL ALLOGENEIC
TRANSPLANTATION (ASCT) PREPARED WITH REDUCED INTENSITY
REGIMEN (RIC): LEUKEMIA CONTROL REQUIRES ADEQUATE PRE
GRAFT CHEMOTHERAPY AND POST GRAFT GVHD
Faucher, C.1, Boiron, J.M.2, Mohty, M.1, Bay, J.O.3, Perreau, V.2,
Bilger, K.1, Vey, N.1, Stoppa, A.M.1, Coso, D.1, Ladaique, P.1, Ma-
raninchi, D.1, Blaise, D.1 1. Institut Paol-Calmettes, Marseille, France;
2. Hoˆpital Haut Leveˆque, Pessac, France; 3. Centre Jean Perrin, Cler-
mont Ferrand, France.
We report a prospective investigation of HLA identical ASCT
for pts with CR1 AML presenting contra-indications to standard
ASCT (age   50 and/or any comorbidity) and/or poor progno-
sis features. All pts received a RIC: Fludarabin (30mg/m2/j), Busul-
fan (8mg/kg) and thymoglobulin (2.5 mg/m2). This investigation
aimed to treat these pts with the best chemotherapy standard
followed with an allogeneic immunotherapy. Thus intensity of
chemotherapy prior to ASCT was increased stepwise and concom-
itantly immunosuppressive intensity of RIC was decreased. We
treated 26 pts (Age: 52 (26-60); M/F: 11/15) (age  50:19;
previous aspergillosis: 5, high WBC count: 6; secondary leukemia:
5; CR after 2 inductions: 4; poor cytogenetics: 8).All pts received
GVHD prophylaxis (CSA:15 ; CSAMTX:6; CSAMMF:5) and
either BM (10) or PBSC (16) graft). ASCT was performed without
any previous intensive chemotherapy (Group 1: N  5), after 1
cycle of high dose aracytine (3g/m2x2/jx4) idarubicin (12mg/m2/
jx2) (HIDAC) (Group 2; N  15) or after HIDAC and an autol-
ogous PBSCT prepared with melphalan (140mg/m2) (Group 3:
N  6). Allo PBSCT was performed 30 to 60 days after last
chemotherapy. Fludarabine was decreased from 180 to 120 mg/m2
and thymoglobulin from 10 to 2.5 mg/m2. On October 2003, with
a follow-up of 19 months (2-59), all pts engrafted achieving full
chimerism on day 60(30-90). 6 presented grade 2 aGVHD (Cu-
mulative incidence (CI)  23%) and 10 cGVHD (CI  42%).
Owerall 2 pts died from transplant toxicity (TRM) (TRM CI 
8%) and 10 relapsed (Relapse CI  38%) for an overall 2 year
survival (OS) probability of 57%. All pts in group 1 relapsed and 1
is long term survivor after second transplant. Of the 15 pts with
HIDAC alone, 5 relapsed (relapse CI: 33%), 1 died from GVHD
(TRMCI: 7%) for a 2 year OS 68%. Of the 6 pts with HIDAC and
Auto PBSCT, none relapsed and 1 died from GVHD. Relapse was
statistically associated with the absence of pre-graft intensive che-
motherapy (p  0.02), the use of higher dose (5-7.5 mg) of ATG
(p  0.003) and the absence of acute and chronic GVHD (p 
0.001). Longer survival was associated with the use pre-graft in-
tensive chemotherapy (p 0.04). We conclude that in a population
of high risk pts, RIC ASCT is associated with a low TRM and a
potent GVL effect if adequate prior chemotherapy is delivered and
conducts to high Os. Impact of prior Auto PBSCT seems beneﬁc
but needs longer follow-up and higher number of pts and is
presently evaluated.
160
EVALUATION OF BONE MARROW TRANSPLANATION AND ARSENIC
TRIOXIDE IN THE TREATMENT OF AML M3 (AN EXPERIENCE IN IRAN)
Ghavamzadeh, A., Iravani, M., Jafari, M., Gholibeikian, S., Alimo-
ghaddam, K., Aghdami, N., Bahar, B., Mousavi, A. Hematology-
Oncology & BMT Research Center,Tehran University of Medical Sci-
ences, Tehran, Islamic Republic of Iran.
Background: Acute promyelocytic leukemia characterized by
t(15;17) and PML/RARa gene fusion. Material Methods: From
April 1993 till March 2003, 24 patients treated under BMT. Ten
Autologous and 14 allogeneic transplantations were done. Sixteen
peripheral bloods and 8 bone marrows were used as graft. Disease
status before transplantation was CR1: 21, CR2: 1 and 1st relapse:
2. Conditioning regimen in autologous transplantation was Ara–C
(1000 mg/m2/bd x 3 days)  Cyclophosphamide (60mg/kg x 2
days)  Etoposide (500mg/m2 x 3 days) and in allogeneic form the
main regimen was Busulfan (4mg/kg x 4 days) Cyclophospha-
mide (60mg/kg x 2 days). Other conditioning regimen, which used
in 2 patients in allogeneic transplantation, was Fludarabin (40mg/
m2/day/IV infusion x 5 days)  Busulfan (4mg/kg/day x 4 days).
Cyclosoporin and Methotrexate were used as prophylaxis drugs for
GVHD. The engraftment was evaluated with time of ANC 
500x108. Arsenic trioxide was used as other kind of treatment for
AMLm3 in 76 patients from May 2000 till March 2003. Sixty-
seven of patients were new case and 11 were in relapse state.
Arsenic trioxide (0.15 mg/kg/IV infusion for 2-4 hours) was used
from day of diagnosis till CR by morphologic criteria or till 60
days. Results: 70.8 % of patients (17/24) were in sustained CR
after BMT and 76.3% patients (64/76) achieved this state in arsenic
groups. Death occurred in 31.5% of patients (24/76) in arsenic and
20.8% of patients (5/24) in BMT group. The total 1, 3 and 5 years
overall survival (OS) and disease free survival (DFS) was 79.4%,
66.2%, 66.2% and 85%, 56.6% , 56.6% in BMT group respec-
tively. In Arsenic group the total 1 and 3 years OS and DFS was
70%, 63.1% and 89.6%and 73.9% respectively. Conclusion: Al-
though arsenic trioxide is a suitable and economical method for
treatment of AMLM3 but needs a long time for assessment the
efﬁcacy of it. We believe that bone marrow transplantation is a
curable alternative for these patients especially in high-risk form of
disease.
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